Physician profile
Amanda Chism
NPI 1295050672
$4,454.51
in general payments reported to CMS, 2019-2025
33 companies · $677 in 2025
The $677 reported for 2025 was more than what 79% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $531 · 2020: $337 · 2021: $1,118 · 2022: $529 · 2023: $631 · 2024: $632 · 2025: $677.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,939.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,939.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,259.45 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $721.82 | 2020-2025 | |
| Lilly USA, LLC | $385.62 | 2019-2025 | Mounjaro, Zepbound |
| Biohaven Pharmaceuticals, INC. | $306.07 | 2020-2021 | |
| Astrazeneca Pharmaceuticals LP | $293.14 | 2019-2025 | Flumist Quadrivalent, Airsupra, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $275.56 | 2019-2024 | Jardiance |
| Takeda Pharmaceuticals U.S.A., INC. | $233.17 | 2019-2023 | Trintellix |
| Merck Sharp & Dohme LLC | $161.14 | 2019-2024 | Gardasil 9, Vaxneuvance, M-M-R II |
| Ultragenyx Pharmaceutical INC. | $106.75 | 2021-2023 | |
| Glaxosmithkline, LLC. | $73.95 | 2019-2024 | Shingrix, Trelegy Ellipta |
| Amgen INC. | $67.93 | 2019-2025 | Repatha, Otezla, Prolia |
| Biohaven Pharmaceutical Holding Company LTD. | $67.53 | 2022 | |
| Exact Sciences Corporation | $63.67 | 2024-2025 | Cologuard Collection Kit |
| Sanofi-Aventis U.S. LLC | $39.72 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $39.40 | 2021-2022 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $38.49 | 2024-2025 | Gvoke Hypopen, Keveyis |
| Vanda Pharmaceuticals INC. | $32.59 | 2025 | Fanapt |
| Phathom Pharmaceuticals, INC. | $32.48 | 2024-2025 | Voquezna |
| Cranial Technologies, INC | $31.61 | 2024-2025 | Doc Band |
| Abbvie INC. | $27.36 | 2022 | |
| Alnylam Pharmaceuticals INC. | $19.40 | 2025 | Givlaari |
| Axsome Therapeutics, INC. | $18.40 | 2025 | Auvelity |
| Astellas Pharma US INC | $16.28 | 2024 | Veozah |
| Dynavax Technologies Corporation | $16.15 | 2025 | Heplisav-B |
| Teva Pharmaceuticals USA, INC. | $15.92 | 2021 | |
| Corcept Therapeutics | $15.81 | 2024 | Korlym |
| Amarin Pharma, INC. | $15.56 | 2021 | |
| Allergan, INC. | $15.37 | 2019 | |
| Dermira, INC. | $13.77 | 2020 | |
| Lundbeck LLC | $13.33 | 2022 | |
| Supernus Pharmaceuticals, INC. | $13.19 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $12.37 | 2021 | |
| Janssen Pharmaceuticals, INC | $11.51 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Chism listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.